RESMED INC
Financial highlights
| Metric | FY 06/30/26 | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.7B | $5.1B | $4.7B | $4.2B | $3.6B |
| Cost of revenue | $2.2B | $2.1B | $2.0B | $1.9B | $1.6B |
| Gross profit | $3.5B | $3.1B | $2.7B | $2.4B | $2.0B |
| Selling, general & administrative | $1.1B | $993.0M | $917.1M | $874.0M | $737.5M |
| Research and development | $378.3M | $331.3M | $307.5M | $287.6M | $253.6M |
| Operating expenses | $1.6B | $1.4B | $1.3B | $1.2B | $1.0B |
| Operating income | $1.9B | $1.7B | $1.3B | $1.1B | $1.0B |
| Pretax income | $1.9B | $1.7B | $1.3B | $1.1B | $960.5M |
| Income tax expense | $396.1M | $276.8M | $243.8M | $204.1M | $181.0M |
| Net income | $1.5B | $1.4B | $1.0B | $897.6M | $779.4M |
| Balance Sheet | |||||
| Cash and equivalents | $1.5B | $1.2B | $238.4M | $227.9M | $273.7M |
| Current assets | $4.3B | $3.5B | $2.4B | $2.4B | $1.9B |
| Total assets | $9.0B | $8.2B | $6.9B | $6.8B | $5.1B |
| Current liabilities | $1.4B | $1.0B | $910.7M | $758.5M | $689.3M |
| Total liabilities | $2.4B | $2.2B | $2.0B | $2.6B | $1.7B |
| Total debt | $659.4M | $668.3M | $707.2M | $1.4B | $775.2M |
| Stockholders' equity | $6.6B | $6.0B | $4.9B | $4.1B | $3.4B |
| Cash Flow Statement | |||||
| Cash from operations | $1.8B | $1.8B | $1.4B | $693.3M | $351.1M |
| Depreciation and amortization | $201.3M | $198.5M | $176.9M | $165.2M | $159.6M |
| Stock-based compensation | $104.3M | $91.7M | $80.2M | $71.1M | $65.3M |
| Capital expenditure | $156.3M | $89.9M | $99.5M | $119.7M | $134.8M |
| Free cash flow | $1.6B | $1.7B | $1.3B | $573.6M | $216.3M |
| Dividends paid | $349.7M | $310.9M | $282.3M | $258.3M | $245.3M |
| Share repurchases | $700.0M | $300.0M | $150.0M | $0 | $0 |
| Impairments | — | — | — | $0 | $0 |
Shares outstanding 144.3M · Free float 94.9%
Annual filing data through FY ended June 30, 2026; float as of September 8, 2026.